To investigate the antitumor effect of interferon-alpha 2a (IFN-α2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression.
Thirty nude mice bearing orthotopic xenografts of a human HCC tumor (LCI-D20) were divided into control, capecitabine, IFN-α2a, and combination (capecitabine plus IFN-α2a) groups. Tumor growth was determined by measuring the tumor volume. An enzyme-linked immunosorbent assay (ELISA) was used to study the TP expression in the cancer tissues of the liver.
IFN-α2a enhanced the sensitivity of the LCI-D20 tumor response to capecitabine treatment. The tumor volume was significantly reduced in the capecitabine (455±236 mm3), IFN-α2a (248±114 mm3) or combination (46±29 mm3) treatment groups as compared to the control (1,033±146 mm3) (P<0.01). A significant difference was also found between the single treatment (capecitabine or interferon) and combination treatment group (P<0.01 and P<0.05, respectively). IFN-α2a up-regulated TP expression in LCI-D20 tumor. An approximate 1.5-fold increase in TP expression was observed in the mice which received IFN-α2a treatment compared to the control mice.
IFN-α2a enhanced the antitumor effect of capecitabine on HCC in nude mice, which might be ascribed to the up-regulation of TP expression in liver cancer tissues by IFN-α2a.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
enzyme-linked immunosorbent assay
tumor necrosis factor–alpha
maximum tolerated dosage
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493
Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast cancer. Cancer 92:1759–1768
Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H (1993) Cytokines in duce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32:333–338
Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine of 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127–134
Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y (1992) Angiogenic factor. Nature (Lond) 356:668
Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (Lond) 338:557–562
Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorourcil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol l55:1091–1097
Ishitsuka H (2000) Capecitabine: preclinical pharmacology studies. Invest New Drugs 18:343–354
Li G, Kawakami S, Kageyama Y, Yan C, Saito K, Kihara K (2002) IFN gamma-induced up-regulation of PD-ECGF/TP enhances the cytotoxicity of 5-fluorouracil and 5’-deoxy-5-fluorouridine in bladder cancer cells. Anticancer Res 22:2607–2612
Meropol NJ (1998) Oral fluoropyrimidine in the treatment of colorectal cancer. Eur J Cancer 34:1509–1513
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and caner tissue. Eur J Cancer 34:1274–1281
Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, Kirchner H, Atzpodien J (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83:583–587
Okuda K (1980) Primary liver cancers in Japan. Cancer 45:2663–2672
Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156
Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito R (1998) The oral fluorouracil prodrugs. Oncology 12:48–51
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019
Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297
Schwartz EL, Wan E, Wang FS, Baptiste N (1998) Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 58:1551–1557
Sun FX, Tang ZY, Liu KD, YeS, Xue Q, Gao DM, Ma ZC (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239–243
Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A:1227–1232
Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol 17:1915–1925
Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL (2000) High-dose and long-term therapy with interferon-alfha inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43–48
Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL (2000) Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57–61
Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Xiao YS, Shi YH, Li XM, Sun QM, Liu YK, Ye SL (2003) Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of PD-ECGF. Clin Cancer Res (accepted)
We thank Nippon Roche Research Centre (Kanagawa, Japan) for providing capecitabine and Hoffman-La Roche (Shanghai, P.R. China) for providing IFN-α2a.
Financial support: the authors are grateful for financial support from the Shanghai Nature Science Foundation (01ZB14010), the Shanghai Science Foundation for Colleges and Universities (02JG05035), the Foundation for “One Hundred Doctors of Project” of Shanghai Health Bureau (97BR029) and the Key Laboratory Of Carcinogenesis And Cancer Invasion (Fudan University), Ministry of Education, P.R. China
About this article
Cite this article
Xiao, Y., Tang, Z., Fan, J. et al. Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. J Cancer Res Clin Oncol 130, 546–550 (2004). https://doi.org/10.1007/s00432-004-0565-8
- Thymidine phosphorylase
- Hepatocellular carcinoma